Valuing R&D Projects in a Portfolio: Evidence from the Pharmaceutical Industry

Understanding the value of a product development project is central to a firm's choice of project portfolio. The value of a project to a firm depends not only on its properties but also on the other projects being developed by the firm. This is due to interactions with the other projects that address the same consumer need and require the same development resources. In this study, we empirically investigate the structure and significance of these portfolio-level project interactions. Using a self-developed pharmaceutical industry data set, we conduct an event study around the failure of phase III clinical trials and their effect on the market valuation of the firm. The study exploits the natural experiment of a product development failure to give us a measure of the value of a drug development project to a firm. We then explain the variance in the value of projects based on interactions with other projects in the firm's portfolio. We find that the presence of other projects targeting the same market and a build-up of projects that require the same development resources reduce the value of a development project. In addition to providing evidence on the significance and structure of these portfolio-level project interactions, the empirical model estimated in this paper also provides a data-driven approach to valuing projects that may be relevant to licensing transactions.

[1]  R. Lucas.  Optimal Management of a Research and Development Project , 1971 .

[2]  J. Patell.  CORPORATE FORECASTS OF EARNINGS PER SHARE AND STOCK-PRICE BEHAVIOR - EMPIRICAL TESTS , 1976 .

[3]  Jerold B. Warner,et al.  MEASURING SECURITY PRICE PERFORMANCE , 1980 .

[4]  David A. Belsley,et al.  Regression Analysis and its Application: A Data-Oriented Approach.@@@Applied Linear Regression.@@@Regression Diagnostics: Identifying Influential Data and Sources of Collinearity , 1981 .

[5]  E. Altman,et al.  Handbook of corporate finance , 1986 .

[6]  T. Devinney,et al.  The Impact of New Product Introductions on the Market Value of Firms , 1993 .

[7]  T. Devinney,et al.  NEW PRODUCT INNOVATIONS AND STOCK PRICE PERFORMANCE , 1992 .

[8]  E. Fama,et al.  Common risk factors in the returns on stocks and bonds , 1993 .

[9]  Paul S. Adler,et al.  From project to process management: an empirically-based framework for analyzing product development time , 1995 .

[10]  Jehoshua Eliashberg,et al.  New Product Announcement Signals and Incumbent Reactions , 1995 .

[11]  E. Fama,et al.  Multifactor Explanations of Asset Pricing Anomalies , 1996 .

[12]  A. Mackinlay,et al.  Event Studies in Economics and Finance , 1997 .

[13]  K. B. Hendricks,et al.  Delays in new product introductions and the market value of the firm: the consequences of being late to the market , 1997 .

[14]  Paula A. Tkac.  A Trading Volume Benchmark: Theory and Evidence , 1998, Journal of Financial and Quantitative Analysis.

[15]  Christoph H. Loch,et al.  Accelerating the process of engineering change orders: capacity and congestion effects , 1999 .

[16]  Christoph H. Loch,et al.  Selecting R&D projects at BMW: a case study of adopting mathematical programming models , 2001, IEEE Trans. Engineering Management.

[17]  Christoph H. Loch,et al.  Parallel and Sequential Testing of Design Alternatives , 2001, Manag. Sci..

[18]  Ely Dahan,et al.  An Extreme-Value Model of Concept Testing , 2001 .

[19]  Sean Nicholson,et al.  Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality , 2002 .

[20]  Christoph H. Loch,et al.  Dynamic Portfolio Selection of NPD Programs Using Marginal Returns , 2002, Manag. Sci..

[21]  Ming Ding,et al.  Structuring the New Product Development Pipeline , 2002, Manag. Sci..

[22]  Robert Jacobson,et al.  The Financial Rewards of New Product Introductions in the Personal Computer Industry , 2003, Manag. Sci..

[23]  Karl T. Ulrich,et al.  50th Anniversary Article: Technological Innovation, Product Development, and Entrepreneurship in Management Science , 2004, Manag. Sci..

[24]  Charles J. Corbett,et al.  The Financial Impact of ISO 9000 Certification in the US: An Empirical , 2004 .

[25]  Christoph H. Loch,et al.  Project Selection Under Uncertainty: Dynamically Allocating Resources to Maximize Value , 2004 .

[26]  Anurag Sharma,et al.  Linking Product Development Outcomes to Market Valuation of the Firm: The Case of the U.S. Pharmaceutical Industry* , 2004 .

[27]  Sheng-Syan Chen,et al.  The Wealth Effect of New Product Introductions on Industry Rivals , 2005 .

[28]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[29]  Charles J. Corbett,et al.  The Financial Impact of ISO 9000 Certification in the United States: An Empirical Analysis , 2005, Manag. Sci..

[30]  Kevin B. Hendricks,et al.  Association Between Supply Chain Glitches and Operating Performance , 2005, Manag. Sci..

[31]  V. Singhal.  Excess Inventory and Long-Term Stock Price Performance , 2005 .

[32]  S. P. Kothari,et al.  Econometrics of Event Studies , 2007 .

[33]  Sheng-Syan Chen,et al.  Intra-Industry Effects of Delayed New Product Introductions , 2007 .

[34]  B. Cheson.  New drug development. , 2009, Clinical advances in hematology & oncology : H&O.